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DEVELOPMENT OF CRISPR-CAS9 
FOR IN VIVO MEDICAL APPLICATIONS 
 
KAVIN ZHU 
 
ABSTRACT 
Clustered Regularly-Interspaced Short Palindromic Repeats (CRISPR) and its 
CRISPR-associated (Cas) proteins have revolutionized genetic engineering. 
Since its discovery, it has supplanted previous methods of gene editing with its 
versatility and ease-of-use. Furthermore, the possibility of developing CRISPR-
Cas9-based treatment plans for genetic therapy has piqued the interest of 
scientists. Much research has been done to evaluate its potential for use in 
medicine as well as the obstacles that prevent it from clinical applications. 
Although CRISPR-Cas9 can be effective at inducing double strand breaks in 
DNA, its overall template insertion efficiency is often not sufficient. By default, 
somatic cells repair damage to their DNA by undergoing nonhomologous end 
joining (NHEJ), which is not compatible with precise gene insertion. For a desired 
sequence to be inserted at the break site, homology directed repair (HDR) is 
required. Several methods of NHEJ inhibition and HDR stimulation have been 
evaluated and were effective at increasing HDR efficiency in vitro, but these 
results cannot be generalized for in vivo environments. Accordingly, results from 
CRISPR-Cas9 research have shown more promise for hematological diseases 
  v 
than for others. In order to address this disparity, additional work on its efficacy in 
vivo must be done. CRISPR-Cas9 has the potential to become the basis of future 
treatments for genetic disorders. Prior to this, treatments will need to account for 
the complex nature of in vivo processes. This thesis examines the current 
literature to gauge how far CRISPR-Cas9 technology is from use on human 
patients. 
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INTRODUCTION 
 
 The science of genetic engineering has progressed considerably in recent 
years, driven by a better understanding of molecular biology and the discovery of 
Clustered regularly-interspaced short palindromic repeats (CRISPR). In 
conjunction with its CRISPR-associated (Cas) proteins and specifically Cas9, the 
CRISPR-Cas9 system has revolutionized gene editing technology.1 Compared to 
previous methods of gene editing, CRISPR-Cas9 systems are more attractive to 
researchers for multiple reasons, including ease-of-use, adaptability, and cost-
efficiency. These qualities have greatly enhanced the efforts of scientists 
conducting research in genetic engineering and facilitates the possibility of 
developing CRISPR-Cas9-based applications in medicine. 
The increasing attention of scientists and financial investors in this field of 
science is no surprise, given its potential as a solution to many medical issues 
that afflict humanity today. Theoretically, CRISPR-Cas9-based techniques can 
be employed when treating all diseases with a genetic disorder as the underlying 
cause. This encompasses hereditary disorders, such as sickle cell disease and 
cystic fibrosis, as well as those caused by postnatal DNA mutations, like various 
types of cancers. Although these diseases are similar in their origin, it is by far 
easier to develop treatment options for hematological diseases due to the 
inherent properties of hematopoietic stem and progenitor cells (HSPC). Given 
their capabilities to renew and differentiate, a few genetically engineered HSPCs 
 2 
 
have the potential to regenerate an entire functional, hematopoietic system in 
patients suffering from some hematological disease.2 On the same note, some of 
the most promising experiments on CRISPR-Cas9 research have been 
conducted on HSPCs. This paper seeks to analyze the results of these studies 
as well as others in order to describe the obstacles that scientists currently face 
and must overcome before CRISPR-Cas9-based treatments become viable for 
other diseases caused by genetic disorders. 
While it has been used successfully to edit the genome of a human 
embryo by Huang et al., the use of CRISPR-Cas9 to treat diseases in adult 
humans is much more complex.3 As a zygote matures to become an embryo and 
eventually an adult, other problems arise. Like the multiplying number of cells, 
the difficulty of developing a feasible treatment increases, too. An issue that must 
be addressed when designing CRISPR-Cas9-based treatments is its route of 
administration: how can the proposed treatment be delivered at an efficient rate 
to the targeted cells? To answer this, one also has to consider how effectively the 
CRISPR-Cas9 system can modify the targeted DNA sequence in relation to other 
homologous sequences that are present in the extensive human genome. Failure 
to address these problems can lead to undesirable off-target effects and render 
the treatment unfeasible.  
In addition to technical issues, the development of CRISPR-Cas9 
technology has been complicated by ethical and legal issues as well. As quickly 
as it emerged as the prime method of gene editing, CRISPR-Cas9 also inherited 
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the ethical issues of genetic engineering. After the Huang paper was published, 
multiple groups called for a halt to such experiments, declaring that a 
conversation regarding the ethics of CRISPR-Cas9 technology must precede its 
perfection.4 These are the same general issues that faced previous gene editing 
methods. Moreover, controversy over who should be credited with the discovery 
of CRISPR-Cas9 has led to litigation between institutions. In February of 2017, 
the U.S. Patent Trial and Appeal Board ruled in favor of the Broad Institute.5 This 
is only the beginning of an intense, legal battle that will decide ownership of the 
highly-contested intellectual property linked to CRISPR; the decision is expected 
to be appealed by the University of California at Berkeley. Ultimately, the overall 
progress of CRISPR research may be hampered as companies and institutions 
file for patents to lay claim to various niches of CRISPR technology.  
 
CRISPR-Cas9 Systems 
CRISPRs were first discovered in E. coli in 1987 and many other species 
of bacteria soon after.1 Due to their ubiquity in bacterial genomes, scientists 
hypothesized that they may have an important evolutionary function, later 
identified as an immune system to protect against bacteriophages. CRISPRs are 
clusters of short, palindromic repeats (SPR) of deoxyribonucleic acid (DNA) 
interspaced with spacer DNA (Figure 1). Unlike SPRs, sequences of the spacer 
DNA are unique and correspond to the foreign DNA of bacteriophages captured 
from previous infections.6 Further upstream of the SPRs, Cas genes can be 
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found and these generally encode for helicases and nucleases to help unwind 
and cut DNA, respectively. Also, a leader sequence can be found adjacent of the 
SPRs and is important for promoting transcription.  
 
Figure 1. General layout of CRISPR-Cas locus. Unique spacer DNA is 
interspaced with SPR’s and preceded by leader sequence. Cas genes are found 
upstream. 
 
Cas9 is an endonuclease that can be found in Staphylococcus pyogenes, 
which utilizes crRNA (CRISPR RNA) and tracrRNA (trans-activating crRNA).5 
CrRNA is partially transcribed from the spacer DNA, allowing it to target a 
desired sequence of foreign DNA. TracrRNA forms a duplex with pre-crRNA and 
is important for its maturation in crRNA. It has since been re-engineered by 
Doudna and Charpentier into a simpler system which combines the tracrRNA 
and crRNA into a single guide RNA (gRNA).7 Together, the gRNA directs the 
Cas9 protein to the correct DNA sequence for cleavage (Figure 2). 
How does Cas9 differentiate between native and foreign DNA when both 
are identical in sequence? Without some sort of signal, Cas9 can possibly cleave 
the bacterium’s own DNA, which can induce apoptosis. Through evolution, 
bacteria have also utilized protospacer adjacent motifs (PAM) to protect their own 
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DNA. These are short sequences of usually 2-6 base pairs (bp) adjacent to the 
targeted DNA sequence that is usually present only in the invaders genome. In 
other words, they are not found with spacer DNA in the bacterial genome. For 
Cas9 to bind tightly enough to the target DNA sequence and cleave it, a PAM 
must be present. Thus, endogenous DNA is protected and one can see that 
CRISPR-CAS9 systems must be designed with specific PAMs to work effectively.  
 
 
 
 
Figure 2. CRISPR-Cas9 mechanism. In a theoretical bacterial cell, crRNA and 
tracrRNA is transcribed from the CRISPR locus. Complementary sequences 
allow them to pair and then associate with Cas9 nuclease. CrRNA binds 
complementarily to viral DNA. Cas9 recognizes PAM sequence in viral DNA, 
binds tightly, and cleaves it. 
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NHEJ vs HDR 
When the CRISPR-Cas system is transcribed in a bacterium, it produces a 
protein-RNA complex capable of cleaving the invading bacteriophage DNA and 
neutralizing its threat. The CRISPR-Cas system has served its purpose and the 
bacterium is safe. When applying this to gene therapy, scientists must also plan 
for the rejoining of the cleaved ends. In humans, two major pathways of DNA 
repair exist. Of the two, nonhomologous end joining (NHEJ) is the more common 
pathway as it can occur in all cells.8 During NHEJ, cell machinery repair DNA 
double strand breaks (DSB) by joining the two ends regardless of the original 
sequence. NHEJ results in random insertion or deletion of nucleotides (indels) 
and this unpredictability is problematic with genetic therapy. While it is possible to 
knock out genes by creating indels with this pathway, NHEJ cannot be reliably 
used to insert specific sequences (Figure 3, left side) 
Homology directed repair (HDR) is the other pathway and is much more 
precise, which is appropriate for insertion of specific sequences (Figure 3, right 
side). When a DSB in DNA is detected, cell repair machinery can direct one of 
the broken strands to a template strand.9 That broken strand can then be 
elongated at the 3’ end until it is long enough to pair complementarily to the other 
broken strand. Finally, nucleotides are added to the two broken strands and 
ligated, completing the repair. This pathway is more suitable for genetic therapy 
and can be incorporated into CRISPR-Cas9 systems by including a donor 
plasmid with the desired repair template.  
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Figure 3. Possible outcomes of DNA repair through NHEJ or HDR. After a 
DSB, DNA repaired through NHEJ will likely result in indels. HDR utilizes a 
template for precise correction. 
 
 
CRISPR-CAS9 IN HEMATOLOGY 
 
 Gene therapy-based treatments for different hematological diseases share 
common principles and follow a general procedure. This is true of CRISPR-Cas9 
as well as previous methods of gene editing. Based on their aforementioned 
properties, hematopoietic stem and progenitor cells (HSPC) will likely be the one 
of the first targets of such treatments. A few milliliters (mL) of blood drawn from a 
patient will provide enough HSPCs to be modified in vitro. This allows 
researchers to avoid complex effects from cellular processes that are difficult to 
account for in vivo. Once viable, genetically engineered cells have been 
identified, they can be selected for and amplified in culture. For this reason, 
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improving editing efficiency here is not as large of a concern as it would be for 
other cell types for the treatment of other diseases. Another complication of some 
hematological diseases, specifically blood cancers, is the necessity to eradicate 
the remaining, unmodified HSPCs responsible for the disease. To do so, 
methods such as chemotherapy and radiotherapy are often employed in 
conjunction with hematological disease treatments. After these steps have been 
completed, clones of the corrected HSPCs can finally be introduced to a patient’s 
body and replenish the hematopoietic system. 
 
Combating HIV with Genetic Engineering 
Human immunodeficiency virus (HIV) is a retrovirus that can deplete an 
infected person’s immune system, making them more prone to other infections 
and illnesses. It is able to infect immune cells by recognizing certain receptors, 
namely cluster of differentiation 4 (CD4) and C-C chemokine receptor 5 
(CCR5).10 These two receptors are present on both macrophages and CD4+ T 
cells, which enables HIV to enter and replicate in them. This gradually decreases 
a person’s immune cell counts and leads to the development of acquired 
immunodeficiency syndrome (AIDS).  
One of the earlier examples of genetic engineering being used in clinical 
applications was conducted by Tebas et al. on HIV-positive patients.2 CD4+ T 
cells were obtained from these patients and modified at the CCR5 gene locus 
using zinc finger nucleases (ZFN). Although ZFN’s are not as proficient at 
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precise gene insertion as CRISPR-Cas9 systems, they can be used effectively to 
knock out genes.11 No longer expressing CCR5, scientists hypothesized that the 
modified CD4+ T cells should be less susceptible to invasion by HIV. Hence, the 
survival rate of these cells should be improved and the number of CD4+ T cells 
should be replenished. Results were promising – all patients had increased 
CD4+ T cell counts post-transfusion and the median cell count increased 
significantly from 448 per cubic millimeter to 1517 per cubic millimeter at week 1. 
By editing the genomes of autologous CD4+ T cells in vitro and reintroducing 
them to the patients, Tebas et al. were able to create HIV-resistant immune 
systems in infected patients. Earlier studies like this one were important in 
proving the effectiveness of utilizing genetic engineering to treat hematological 
diseases. 
 
Using CRISPR-Cas9 to Treat SCD 
The feasibility of using CRISPR to treat hematological diseases was 
demonstrated by Wen et al. in their study to treat sickle cell disease (SCD) by 
genetically modifying HSPCs.12 SCD is an autosomal recessive condition in 
which a person lacks a copy of the normal hemoglobin A (HbA) allele.13 This is 
caused by a point mutation from an A to T, converting a glutamic acid codon 
(GAG) to a valine (GTG) codon in the hemoglobin beta chain (HBB) gene (Figure 
4a). Under stress, the absence of HbA and the expression of abnormal 
hemoglobin S (HbS) causes the the sickling of red blood cells (RBC).  Sickle-
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shaped RBCs have a tendency to clump together and stick to blood vessels, 
which can lead to complications such as anemia, stroke, and organ damage.14 
People who are heterozygous with HbS/HBB alleles are considered carriers of 
the sickle cell trait (SCT); both HbA and HbS can be found in their RBCs. The 
amount of HbA present in the blood is enough so that SCT carriers usually do not 
suffer from the same symptoms as those with SCD.15 
 Prior to conducting their main experiment, Wen et al. wanted to assess the 
baseline efficiency of their CRISPR-Cas9 system.12 Human erythroleukemia 
(HEL) cells carrying two normal copies (HBB/HBB) were transformed via 
electroporation with Cas9 mRNA and sgRNA for HbS in two separate steps to 
create HbS/HBB and HbS/HbS genotypes. Next, to mimic SCD treatment, the 
engineered HbS/HbS cells were transformed again with CRISPR-Cas9 
components corresponding to the HbA allele (Figure 4b). The conversion of the 
HbS/HbS to HbS/HBB genotype effectively “cures” SCD, since SCT carriers do 
not experience the same symptoms.  
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Figure 4. Genetically modified HEL cells. (A) HEL cell is converted from SCD 
to SCT with valine to glutamate conversion in position 6. (B) Editing efficiency of 
HbS/HbS cells to HBB/HbS cells was 8.5%. (C) Genetically modified RBC’s 
(HBB/HbS) cells are less likely to sickle. 
Adapted from Wen et al., 2017. 
 
Finally, HSPCs with the HbS/HbS genotype were collected from SCD 
patients. Both erythroid and granular/monocytic progenitor colonies were formed 
and underwent the aforementioned CRISPR-Cas9 treatment. This resulted in 
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HbS/HBB editing efficiencies of 9.0% and 8.6%, respectively, and is in line with 
editing efficiencies of the HEL cells. These percentages are sufficient for 
producing viable colonies. As mentioned previously, increasing editing efficiency 
is not as important for cases like these because cells that had been modified can 
be identified and selected for. The resulting edited HbS/HBB erythroid progenitor 
cells were cultured and amplified in vitro to produce viable and mature RBC’s for 
cell sickling tests. Under induced hypoxic conditions that promote cell sickling, 
the RBC offspring of the modified HSPC’s sickled less in comparison to RBC’s 
obtained directly from SCD patients and RBC’s developed in vitro without 
genome-editing (Figure 3c).  
The findings of this study provide compelling evidence of how CRISPR-
Cas9 technology can be applied to treat hematological diseases and may be 
even safer than present treatments. Currently, the only way to treat SCD is 
through allogeneic bone marrow transplant.16 However, there may be more 
obstacles associated with this than with CRISPR-Cas9 based treatments. Not 
only is it difficult to locate a suitable donor, performing the procedure comes with 
serious risks. For instance, in a study with ten male SCD patients who had 
undergone either bone marrow transplant or hydroxyurea treatment (to increase 
fetal hemoglobin), nine of those patients becoming azoospermic or 
oligozoospermic.17 Wen et al.’s assessment of the in vitro functionality of the 
modified cells are promising, but additional research on the possible side effects 
of reintroducing the modified HSPCs to SCD patients is warranted.10 
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Using CRISPR-Cas9 to Treat Leukemia  
 Leukemia is a form of hematological cancer that can occur from mutations 
in the DNA of HSPCs. While there is no single known cause of leukemia, the 
mutation of proto-oncogenes or tumor suppressor genes are known risk factors.18 
This can lead to the overproduction of abnormal white blood cells, which cannot 
fight infections effectively and inhibit the production of functional white blood 
cells. The additional sex combs like 1 (ASXL1) gene encodes a protein that 
functions as an epigenetic modifier and tumor suppressor.19,20 Mutations of this 
gene are commonly found in myeloid malignant diseases, including acute and 
chronic myeloid leukemia.21,22 Valletta et al. evaluated the effectiveness of using 
a CRISPR-Cas9 system to correct the mutation.23  
The human myeloid leukemia KBM5 cell line, which is homozygous for the 
mutation and does not express the ASXL1 protein, was transfected with 
CRISPR, template DNA, and a vector containing one of three sgRNA’s. This 
yielded 2%, 0.46%, and 1.4% heterozygous correction, respectively as well as 
1.63% and 1.13% homozygous correction for two of the three sgRNA’s. These 
percentages were in line with rates (0.1%-3.3%) of precise gene insertion via 
HDR from previous studies.24 Western blot analysis showed that protein 
expression was restored in the ASXL1-corrected clones. Additionally, cell growth 
was significantly suppressed in ASXL1-corrected clones compared to 
uncorrected KBM5 cells. Analysis of the top five predicted off-target sites 
revealed zero mutations in the ASXL1-corrected clones using Sanger 
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sequencing. The inherently low rates of HDR could be related to the absence of 
off-target mutations. Without exactly homologous target sequences or PAMs, 
affinity of the CRISPR-Cas9 complex to off-target sites may be even lower than 
expected. As long as viable modified cell colonies can be created, a lower HDR 
efficiency rate may be beneficial for in vitro experiments for the suppression of 
off-target mutations. 
Finally, to determine in vivo efficacy, KBM5 and ASXL1-corrected cells 
were xenografted into non-obese diabetic-severe combined immunodeficiency-
IL-2Rgamma null mice. Those xenografted with the ASXL1-corrected cells had a 
significantly higher survival rate than those xenografted with the uncorrected 
KBM5 cells (Figure 5). These results demonstrate the potential of CRISPR-Cas9-
based applications in the treatment of hematological diseases. While Valletta et 
al. did not detect any off-target mutations, it is possible that side effects not 
observed here in mice may be present in humans.23 Future clinical studies 
should seek to validate these findings as well as further evaluate any unknown 
off-target effects.  
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Figure 5. Survival rate of mice xenografts. Mice xenografted with two 
homozygous ASXL1 mutation corrected clones (labeled 1 and 2) survived 
significantly longer than those xenografted with uncorrected KBM5 clones. 
Adapted from Valletta et al., 2015. 
 
 
 
STRATEGIES FOR OPTIMIZING CRISPR-CAS9 
  
 Studies focusing on CRISPR-Cas9 systems thus far have produced 
encouraging results for its application in treating hematological diseases. Unlike 
hematological diseases, it is difficult to accurately predict the efficacy of 
treatment plans for other diseases with data from in vitro experiments. Before 
CRISPR-Cas9-based treatments can become feasible for other diseases, they 
will likely need to be designed with the consideration of various in vivo factors. If 
the ultimate goal is to establish reliable in vivo medical applications, the inherent 
low HDR efficiency and possible off-target effects must be evaluated. 
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NHEJ is the more common method of DNA repair since it can occur 
throughout the cell cycle, unlike HDR, which is usually only active during the S 
and G2 phase.8 Consequently, the low efficiency of HDR has bottlenecked the 
advancement of CRISPR-Cas9 based applications in medicine. Therefore, 
developing methods to increase HDR frequency could prove to be a valuable 
strategy for enhancing CRISPR-Cas9 systems.  
 
NHEJ Inhibition with Scr7 
An effective approach for increasing HDR frequency is to suppress its 
counterpart. Maruyama et al. hypothesized that it is possible to improve HDR 
efficiency by inhibiting DNA ligase IV, a key enzyme in the NHEJ pathway, with 
Scr7, a small molecule inhibitor.25,26 The efficiency can then be measured by the 
number of sites with the intended insert. Epithelial (A549) and melanoma 
(MelJuSo) cell line derivatives expressing sgRNA and Cas9 were generated and 
cultured in various concentrations of Scr7. It was found that the efficiency of HDR 
increased up to threefold in A549 cells and 19-fold in MelJuSo cells. In order to 
confirm the results seen in MelJuSo cells, chip-based capillary electrophoresis 
and deep sequencing experiments were done and findings were consistent; the 
percentage of deletions decreased and insertions increased when Scr7 was 
added to the cells. 
 Maruyama et al. also evaluated the possibility of increasing HDR 
frequency in mouse zygotes. LPETG, a sortase motif, was used to determine the 
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insertion rate. In the absence of Scr7, both NHEJ-mediated deletion alleles and 
LPETG-inserted alleles were detected. In the presence of Scr7 however, only 
LPETG-insertion alleles were detected. This corresponds with their findings that 
insertion frequency was significantly higher for Scr7-coinjected blastocysts in 
comparison to blastocysts not injected with Scr7.  
 Although these results support the effectiveness of Scr7, more research 
would need to be done before it can be approved for use. DNA damage naturally 
occurs in cells and repair pathways are necessary for correcting these errors. 
Since NHEJ is the default repair pathway for most cells, it is likely that inhibiting 
one of its key enzymes, DNA ligase IV, would result in undesired side effects. For 
instance, Scr7 treatment on mice has been shown to obstruct lymphocyte 
development as DNA ligase IV is required for V(D)J recombination.27 Inhibition of 
NHEJ can also induce apoptosis, so the toxicity of Scr7 needs to be addressed. 
Results from the cell-based experiments suggest that Scr7 toxicity varies 
between different cell types. On the other hand, results of the zygote-based 
experiment revealed that Scr7 treatment neither reduced the viable number of 
injected zygotes nor the number of live pups born from those injected zygotes. 
This may be due to the fact that NHEJ is not as involved in actively replicating 
cells, where HDR is active, as it is in non-dividing cells. Therefore, it would make 
sense that inhibition of DNA ligase IV and NHEJ in zygotic cells would have 
fewer side effects. For the purpose of in vivo applications, the ability of Scr7 to 
inhibit NHEJ in somatic, nondividing cells should be assessed. 
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HDR Stimulation with RS-1 
Another strategy for increasing HDR frequency is to add a stimulating 
compound. Similar to Maruyama et al, Song et al. also hypothesized that 
inhibiting NHEJ or enhancing HDR would increase insertion efficiency.28 In 
addition to Scr7, their experiments also focused on the effects of RAD51-
stimulatory compound 1 (RS-1).29 RAD51 is a eukaryotic protein that is important 
for repairing DSBs via HDR.30  
In their first round of experiments, rabbit embryos co-injected with 
template DNA, Cas9 mRNA, and sgRNA targeting a ROSA26-like locus (RLL) 
were incubated in serial concentrations of either Scr7 or RS-1. In contrast to the 
previously mentioned results, they found that Scr7 treatment did not have any 
effect on knock-in rates, while RS-1 treatment significantly increased knock-in 
rates. Treatment of the embryos with RS-1 or RAD51 mRNA both increased 
knock-in rates by five to six-fold in relation to control samples. This was expected 
and indicates that RAD51 mRNA may be used as a substitute for RS-1 if serious 
off-target effects caused by the administration of RS-1 arise.  
 Based on the previous results, Song et al. conducted in vivo experiments 
in which embryos treated with RS-1 were transferred to recipient rabbits.28 
Results correlated with previous findings: the non-treated embryos had higher 
rates of indel mutations, while the RS-1 treated embryos had significantly higher 
rates of knock-in. These results support the HDR frequency enhancing effects of 
RS-1, but additional work on its in vivo effects is necessary. 
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Delivery with AAV  
 Adeno-associated virus (AAV) has gained popularity as a delivery vector 
in the field of genetic engineering for its nonpathogenic properties. Discovered in 
1965, AAV was classified as a defective virus due to its poor ability to replicate.31 
In 1980, experiments revealed that cell lines infected with adenovirus resulted in 
the production of AAV and that copies of the AAV genome had been found in the 
host genome.32 The dependence of AAV on adenovirus to initiate replication is 
precisely responsible for its low infectivity, which is valuable when used as a 
vector for gene transfer. In human cells, AAV is known to integrate itself at the 
adeno-associated virus integration site 1 (AAVS1) of chromosome 19.33 While 
integration at off-target sites do occur, it happens at a negligible frequency. This 
certainty is important for genetic engineering research as it minimizes the risk of 
off-target mutagenesis and off-target effects. Finally, multiple serotypes of AAVs 
exist, with varying expression levels and tropism for different organs. This gives 
scientists the flexibility to optimize treatments by selecting the AAV serotype 
most relevant to the disease or tissue type.34  
 In eukaryotic organisms, immune systems exist in order to protect the host 
from foreign molecules or pathogens that can be harmful to itself. Any nonnative 
molecule, including Cas9, can potentially elicit an immunogenic or allergic 
response in the host. For reasons stated in the previous paragraph, AAVs are 
widely considered nonpathogenic and suitable for genetic therapy.  
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Limitations do exist, however. AAVs naturally have a linear, ssDNA 
genome approximately 4.7 kilobases long. This means that the cloning capacity 
of the AAV vector is restricted to lengths shorter than 4.7 kilobases and makes it 
incompatible with larger genes.3 The most commonly used Cas9 ortholog is 
SpCas9, which originates from S. pyogenes and is 4.2 kilobases long. This 
leaves little space for additional sequences and limits the design of gene 
cassettes. Alternatively, SpCas9 has the least restrictive PAM requirement in 
comparison to other Cas9 orthologs and has the largest number of target sites 
available, which is significant for optimizing efficiency. Nevertheless, other Cas9 
orthologues can be used under appropriate circumstances. For example, smaller 
Cas9 orthologs from other bacteria, such as Staphylococcus aureus, have been 
developed.35 However, the PAM requirements of smaller Cas9 orthologs will be 
stricter and may not be compatible for targeting certain gene loci. 
Reducing the size of SpCas9 is an effective strategy to create vector 
space for other genetic components while maintaining its repertoire of target 
sites. Chew et al. hypothesized that splitting SpCas9 at its disordered linker 
(Valine713-Aspartate718) and subsequent reconstitution in vivo by split-intein 
protein trans-splicing will relink the two lobes without loss of function.36 Analysis 
revealed that the reconstituted SpCas9 freed over two kilobases for additional 
elements and demonstrated full activity. Consequently, this version of SpCas9 
was used for their experiments. With the extra space, a tripartite activator, VP64-
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p65-Rta (VPR), was incorporated for upregulating gene expression of the target 
sequence.37   
To determine the effectiveness of delivering CRISPR-Cas9 via AAVs, 
Chew et al. conducted in vivo experiments in which mice were injected 
intramuscularly with AAV-Cas9-gRNA’s targeting the Mstn, Fst, Pd-l1, and Cd47 
gene loci.36 These mice expressed Pd-l1 and Cd47 at levels two-fold greater than 
control mice injected only with AAV-Cas9-VPR-gRNA’s targeting Mstn and Fst, 
proving that AAV-CRISPR-Cas9 is capable of regulating transcription in vivo.  
Next, Chew et al. assessed potential immune response elicited by their 
system. Regardless of how it was delivered, presence of Cas9 in the adult tibialis 
anterior muscle led to enlargement of the draining lymph nodes and increased 
immune cell counts. On the other hand, delivery of the same vectors without the 
Cas9 coding sequence did not induce any significant changes. This suggests 
that the host immune response can mainly be attributed to Cas9. On the other 
hand, it was observed that both Cas9 and AAV evoked a humoral response. The 
coupling of CRISPR-Cas9 to AAVs is beneficial for delivery, but it is unlikely that 
the host immune response can be completely suppressed. 
Interestingly, gene expression for production of dendritic cells and T cells 
were upregulated in muscles treated with AAV9-Cas9-VPR-gRNAs. Mature 
cytolytic CD8+ T cells can cause tissue damage, but results indicated that only 
gene expression corresponding to naïve or immature T cells were increased. 
Further analysis revealed that genes encoding key CD8+ T cell differentiation 
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signals, such as interleukin-12 (IL-12), were not significantly higher at two weeks 
post-treatment. To characterize the extent of CRISPR-Cas9-AAV-induced 
immune responses, interleukin-2 (IL-2) and perforin (Prf1) levels were measured. 
IL-2 is a cytokine required for CD8+ T-cell differentiation, while Prf1 is released 
by mature CD8+ T cells and natural killer cells (NK) to attack their targets. Levels 
of these signals measured within muscles treated with AAV9-Cas9-VPR-gRNAs 
were similar to basal levels, implying that cytolytic activity was minimal. Levels of 
cellular damage were quantitatively assessed by observing the fraction of 
centrally nucleated microfibers, which is indicative of myofiber degeneration and 
repair. In line with basal levels of differentiation signals, significant levels of 
muscle cell damage and repair were not observed at two weeks post-treatment. 
In muscles electroporated with DNA encoding Cas9, both IL-2 and perforin levels 
were significantly higher two weeks post-treatment, indicating myofiber 
degeneration.  
The data obtained by Chew et al. reveals that Cas9 presence in vivo will 
likely elicit an immune response from the host.36 Co-administration of 
immunosuppressants is an option, but may not be optimal as it can lead to other 
side effects. Moreover, it was shown that Cas9 integration into AAV can mitigate 
most of its inflammatory effects without additional off-target effects. These results 
support that transfection of somatic cells with AAV can be viable delivery method 
for future in vivo CRISPR-Cas9 applications. Of course, additional concerns must 
be addressed in this case where genes encoding CRISPR-Cas9 is integrated 
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into a host’s genome. In a scenario where an AAV-treated patient has been 
completely cured, the continued and unnecessary production of CRISPR-Cas9 
products may be detrimental. Before any possible in vivo clinical application, a 
method also must be developed to regulate the transcription of the inserted 
CRISPR-Cas9 genes. 
 
 
NHEJ Inhibition with RNAi and AD4 Proteins 
Although findings from the aforementioned studies do confirm that HDR 
efficiency can be improved by inhibiting NHEJ, the effectiveness of small 
molecule inhibitors on different cell types is unclear. It would be helpful to 
evaluate how effective other methods of NHEJ inhibition influence DNA repair 
pathways and insertion frequencies. Chu et al. conducted experiments that 
suppressed key NHEJ molecules KU70, KU80, and DNA ligase IV by silencing 
genes via RNA interference (RNAi), Scr7, or the co-expression of adenovirus 4 
(AD4) E1B55K and E4orf6 proteins.38  
In order to quantify the ratio of NHEJ to HDR after CRISPR-Cas9-induced 
DSB’s, human HEK293 cells were generated with a traffic light reporter (TLR) 
vector integrated into the adeno-associated virus integration site 1 (AAVS1) 
locus.39 The TLR contains a promoter for expression of a nonfunctional Venus 
(green) gene as well as a red fluorescent (TagRFP) gene in a reading frame 
shifted by 2bp (Figure 6). If a double-strand break is induced by CRISPR-Cas9 
and is repaired via NHEJ, then the HEK293 cells would be expected to express 
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TagRFP in a third of total NHEJ events, assuming that insertions and deletions 
events are randomly distributed. The occurrence of NHEJ can then be 
approximated after multiplication by a factor of three. Also, by providing a repair 
template with an intact Venus coding region, the occurrence of HDR can be 
predicted by measuring the intensity of green fluorescence.  
After viable AAVS1TLR+ cells had been cloned, they were transfected with 
an expression vector for Cas9 and blue fluorescent protein (BFP). This allowed 
the researchers to identify and differentiate between control cells and Cas9+ 
cells, which emit blue fluorescence (BFP+). Chu et al. observed 3% RFP+ and 
5% Venus+ in BFP+ cells, which roughly translates to occurrence rates of 9% 
NHEJ and 5% HDR. As expected, this was significantly higher than the 0.1% 
RFP+ and 0.6% Venus+ occurrence rates in control cells.  
 The AAVS1TLR+ cells were then treated with multiple short hairpin RNAs 
(shRNA) targeting KU70, KU80, or DNA ligase IV. When transcribed, shRNAs 
forms a complex with other proteins called RNA-induced silencing complex 
(RISC). RISC can then target mRNA complementary to its shRNA will either 
cleave or suppress translation of that mRNA. By targeting these key NHEJ 
pathway molecules, Chu et al. wanted to evaluate how gene silencing via RNA 
interference of each would affect overall NHEJ rates.38 As expected, knockdown 
of any of these molecules led to a reduction in NHEJ rates of at least 50% as 
reported by the expression of RFP. Cells transfected with a combination of 
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shRNA targeting both DNA ligase IV and KU70 had the greatest reduction in 
NHEJ activity relative to control cells.   
 
 
Figure 6. TLR system reports HDR efficiency. Diagram of TLR system.  
Adapted from Chu et al., 2015. 
 
 
Next, Chu et al. tested other methods of NHEJ suppression using Scr7 or 
Ad4 E1B55K and E4orf6 proteins, which mediate the ubiquitination and 
proteasomal degradation of DNA ligase IV.40 After selecting for only BFP+ 
transfected cells (Cas9+), Scr7 treatment and co-expression of the Ad4 proteins 
resulted in fourfold and eightfold reduction in the percentage of RFP+ cells 
(NHEJ), respectively. Further Western blot analysis revealed significantly lower 
levels of DNA ligase IV protein in BFP+ cells. It is necessary to mention that 
samples treated with Scr7 or Ad4 had lower overall BFP+ cell numbers relative to 
those without, indicating possible toxicity as a result of apoptotic effects induced 
by NHEJ inhibition.   
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 To analyze HDR rates, the frequency of Venus+ cells amongst BFP+ cells 
was measured in the presence of either the Ad4 proteins or the shRNA’s used 
earlier.38 The percentage of Venus+ cells increased when treated with shRNA’s 
against KU70, KU80, or DNA ligase IV. Scr7 treatment or the combination of 
shRNAs against KU70 and DNA ligase IV were even more effective. In 
agreement with the previous data, co-expression of the Ad4 proteins had the 
highest BFP+ cell percentage. Unsurprisingly, increased HDR frequency was 
inversely correlated with NHEJ frequency in each sample.  
 Finally, the ability of CRISPR-Cas9 to correct a point mutation in a tumor 
cell line was tested. Chu et al. used sgRNA’s to target the Foxo1 gene of mouse 
Burkitt lymphoma (Bl) cells.38 After the Bl cells had been transfected and those 
with the CRISPR-Cas9 components were selected for, clones were created with 
and without the presence of Ad4 proteins. As predicted, HDR frequency was 
higher when both sgRNA’s were used together rather than separately; 81% of 
clones were HDR positive. This was further improved by the addition of Ad 
proteins, where all (100%) clones had undergone HDR with at least one of their 
alleles. Of these clones, those expressing the Ad4 proteins had a higher 
percentage of homozygous mutants than those without. Results from Chu et al.’s 
study reveal that HDR efficiency can be effectively increased through various 
methods. Future studies can be conducted by incorporating the technique most 
appropriate for their purpose. 
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Base Editors 
The low efficiency of the CRISPR-Cas9 system has limited its clinical 
applicability. Cas9 RNA-guided base editing is an exciting genome editing 
strategy because it ignores the constraints of DSB and HDR frequency. Genetic 
engineering with base editors utilize catalytically deficient Cas9 (dCas9) 
synthetically fused to a cytosine deaminase.41 When cytosine (C) is deaminated, 
uracil (U) is formed. Cytosine deaminases generally act on RNA, which is single-
stranded. Those that that act on DNA require single-stranded DNA. When dCas9 
interacts with a targeted sequence, part of the DNA double-helix is unwound and 
unpaired, forming an “R-loop”.42 While this allows the attached cytosine 
deaminase to convert its target nucleotide, cytosine mutations in the non-
template strand can also arise due to the increased exposure to cellular cytosine 
deaminases.43 
 Komor et al. tested the efficiency of different cytosine deaminases and rat 
APOBEC3G was shown to have the highest deaminase activity.44 Subsequently, 
a APOBEC3G-XTEN-dCas9 complex was generated as the first-generation base 
editor (BE1). In vitro assessment of BE1’s ability to edit target cytosines yielded 
an average apparent editing efficiency of 44%. It is known that APOBEC3G has 
a substrate preference for “TC” or “CC”, but Komor et al. hypothesized that the 
tethering of the deaminase to its ssDNA upon dCas9 binding would increase its 
effective concentration and nullify this preference.45 BE1’s ability to edit a double 
stranded DNA was assayed, producing a 50-80% C to U conversion for the 
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substrate strand and 25-40% for the non-substrate stand. Unless the base 
immediately upstream of the target C was a guanine (G), editing efficiency 
seemed independent of the TC/CC preference of APOBEC3G. However, the 
position and type of nucleotide within the PAM did have an effect on editing 
efficiency. BE1 activity was higher in TC > CC > AC > GC, where the second C is 
the target cytosine. It was also observed that the base editor is processive. Once 
the target cytosine is identified, it will convert most, if not all, subsequent 
cytosines to uracils within five bases. 
 These results are promising, but not very applicable in vivo when 
accounting for the transient cellular environment. BE1’s editing efficiency was 
evaluated for six target sites in the human genome. The percentages ranged 
from 0.8% to 7.7%, a significant decrease in comparison to the in vitro results. 
Komor et al. hypothesized that cellular uracil DNA glycosylase (UDG) caused this 
drop-off.44 As a DNA repair response, UDG catalyzes the removal of mismatched 
U’s via base excision repair (BER), generally reversing the incorrect U:G 
arrangement to the original C:G pairing. To counter this response, uracil DNA 
glycosylase inhibitor (UGI) was fused to BE1, creating base editor 2 (BE2: 
APOBEC-XTEN-dCas9-UGI). Assaying BE2 with the six target sites resulted in a 
threefold higher editing efficiency than BE1, with a maximum efficiency of 20%.  
To improve editing efficiency further, BE2 was modified to account for 
other cellular DNA repair processes. In addition to BER, mismatch repair (MMR) 
is another main repair pathway that uses nicks present in the newly synthesized 
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strand to replace an incorrect nucleotide with the correct one. Komor et al. 
hypothesized that intentionally nicking the opposite DNA strand with the unedited 
G would either simulate newly synthesized DNA to induce MMR or simulate 
damaged DNA to induce long-patch BER.44 Therefore, the non-catalytic dCas9 
was adjusted; the original His residue at position 840 of the Cas9 HNH-domain 
was restored, along with its catalytic capabilities. This creates base editor 3 
(BE3: APOBEC-XTEN-dCas9(A840H)-UGI), which can nick the non-edited 
strand containing the G but retains the essential dCas9 Asp10Ala mutation that 
prevents double strand cleavage. These adjustments proved to be worthwhile – 
BE3 increased editing efficiency in human cells by two- to six-fold relative to BE2, 
with a maximum of 37% (Figure 7). The newer versions of base editors were not 
only more proficient at base editing, but also less prone to formations of indels in 
comparison to when double strand breaks are induced.  
 
 
Figure 7. Base editing efficiency on human cells. Editing efficiency of base 
editors on HEK293T cells. 
Adapted from Komor et al., 2016. 
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Next, off-target effects of BE1, BE2, and BE3 were observed at 34 known 
Cas9 off-target sites and 12 known dCas off-target sites.46 Off-target effects were 
detected at a subset of Cas9-specific sites, but none were detected at any dCas-
specific sites. In general, off-target effects of each base editor were present at 
the same off-target sites, with the general trend being BE3 > BE2 >BE1. 
Furthermore, 3,200 cytosines surrounding the 50 target and off-target sites were 
analyzed for C to T mutations and no significant mutation differences were 
observed between nontreated or treated cells.  
Finally, the potential of base editors to correct disease-relevant mutations 
was tested. Apolipoprotein E4 (APOE4), is the most common risk factor for late-
onset Alzheimer’s disease.47 Other variants, such as APOE3r (Arg112 and 
Cys158), are linked to a lower risk of developing the disease. Komor et al. 
treated immortalized mouse astrocytes with BE3 in an attempt to convert APOE4 
to APOE3r.44 Arg158 was converted to Cys158 in 58-75% of total DNA 
sequencing reads. Also, off-target mutations at the third position of codon 158 
and the first position of codon 159 were observed. While these effects were not 
intended, they were not surprising given both of the off-target sites are located 
within the 8-bp-long base editing window and the processive nature of BE3. 
These off-target mutation rates are high enough to be of concern, but neither of 
the two edits alter the amino acid sequence of the APOE3r protein; TGC and 
TGT both encode cysteine, while CTG and TTG both encode leucine. A similar 
experiment was performed on human breast cancer cells (HCC1954) 
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homozygous for the p53 Tyr163Cys mutation, which is strongly associated with 
several types of cancer. Treatment of BE3 resulted in a correction rate of 3.3-
7.6% of cells transformed via nucleofection.  
The results of this study show that BE3-mediated base editing can be 
efficient, albeit with certain drawbacks. By suppressing BER and inducing MMR 
of the unedited strand, Komor et al. were able to obtain base editing efficiencies 
in astrocytes significantly higher than other methods that rely on DSBs.44 Of 
course, the conversion of nearby nucleotides was noticeable, but essentially a 
nonfactor in this case. Clever design of experimental parameters allowed 
researchers to utilize the advantages of base editors and mitigate its 
disadvantages. In terms of application to mutations of other cell types, these 
results suggest that with proper planning, Cas9-based RNA-guided base editing 
can be an effective alternative to CRISPR-Cas9-based therapies.  
 
CRISPR-CAS9 APPLICATIONS IN VIVO 
 
In Vivo Gene Knockdown 
 The potential of using base editors for in vivo application was 
demonstrated when Chadwick et al. delivered a base editor into adult mice livers 
to induce nonsense mutations at the proprotein convertase subtilisin/kexin type 9 
(PCSK9) gene.48 These mice then exhibited significantly reduced plasma PCSK9 
protein levels and plasma cholesterol levels. In addition to this success, indels 
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were not detected at any off-target sites. The PCSK9 gene has become a well-
known target for genetic therapy because its knockdown can reduce the risk of 
developing coronary heart disease.49,50 Ding et al. attempted to disrupt the 
PCSK9 gene in mice using an adenovirus to express the PCSK9 gRNA and 
Cas9 protein.51 These mice expressed substantially lower plasma PCSK9 and 
total cholesterol levels four days after treatment, in line with plasma 
concentrations obtained from PCSK9 knockout mice. Indels of various sizes were 
found at the PCSK9 gene locus, but off-target mutagenesis was not detected at 
potential off-target sites. 
 Rods and cones are the two types of photoreceptors found in the human 
retina. Of the two, cones are more important for their color vision and visual 
acuity. Retinitis pigmentosa (RP) is a genetic disorder characterized by the 
degeneration of the retina and loss of cone photoreceptor function, leading to 
blindness.52 It is theorized that cone loss occurs after rod photoreceptor loss 
exceeds a certain threshold; the disruption of retinal architecture causes nutrient 
deficiencies in cones. One therapeutic strategy is to knockdown the neural retina 
leucine zipper (NRL) gene, an important regulator of photoreceptor development 
and function. Previous studies have shown that disruption of NRL in mature rods 
can prevent its degeneration.53 Following NRL disruption, mature rods lose some 
rod features and gain certain features characteristic of cones. Assuming cone 
loss occurs secondary to rod loss, Yu et al. hypothesized that NRL disruption in 
adult rods will prevent subsequent cone loss and blindness.54 
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Using AAV8 for delivery, Yu et al. injected mice subretinally with a 
combination of AAV-sgRNA-NRL and AAV-Cas9.54 Phenotype changes were 
observed after NRL knockdown. The NRL-treated retinas exhibited larger nuclei 
in comparison with the control retinas. Specifically, some of the photoreceptor 
nuclei displayed smaller heterochromatin regions, which is atypical of rod nuclei 
and characteristic of cone nuclei.55 No mutagenesis was detected at any of the 
ten off-target sites analyzed. However, mild gliosis was observed in both 
CRISPR-EGFP-treated and CRISPR-NRL-treated retinas. Gliosis occurs as a 
response to damage in the central nervous system and involves the proliferation 
of different types of glial cells, which are responsible for protecting and providing 
nutrients to neurons. This suggests an immune response was triggered by 
CRISPR-Cas9 treatment of the retina.  
To determine if this treatment effectively prevented retinal degeneration, 
photopic electroretinography responses were compared between mice treated 
with CRISPR-EGFP or CRISPR-NRL for three months. CRISPR-NRL treated 
mice exhibited much slower decline in b-wave amplitude as well as better 
responses from stimuli with a wide range of flash intensities. In addition, the 
retinas of these mice had higher numbers of photoreceptors as well as higher 
preservation of cone opsin. This was true for all three strains of mice tested and 
suggests that CRISPR-Cas9-NRL treatment was effective at preventing retinal 
degeneration.  
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 Duchenne muscular dystrophy (DMD) is a genetic disease characterized 
by progressively worsening muscle weakness. This is caused by a mutation in 
the Dmd gene encoding dystrophin, whose function is to maintain the integrity of 
muscle cell membranes during contractions.56 Without dystrophin, muscles 
degenerate and can lead to fatal outcomes such as heart failure.  
The insertion of genes is inherently more difficult than disruption because 
it requires HDR. NHEJ is the default repair pathway in somatic cells and the low 
HDR efficiency can certainly hamper the efficacy of CRISPR-Cas9 systems. 
Previously, Long et al. were able to correct a single nonsense mutation at the 
Dmd gene locus using CRISPR-Cas9 to edit germ cells of mdx mice.57 However, 
this is not applicable for in vivo treatment, because HDR rarely occurs in somatic 
tissues. For this reason, their in vivo experiments were centered around 
CRISPR-Cas9-mediated NHEJ of Mdx mice.58 These mice contain a single 
nonsense mutation in exon 23 of the Dmd gene locus and are unable to produce 
functional dystrophin.59 Long et al. sought to restore dystrophin expression in 
Mdx mice through CRISPR-Cas9-induced deletion of the premature stop codon. 
This approach avoids the need for precise HDR-mediated correction and only 
requires the reconstitution of the Dmd open reading frame.  
AAV9, which displays tropism to both cardiac and skeletal muscle, was 
used to deliver CRISPR, Cas9, and sgRNAs intramuscularly. As expected, 
immunostaining of skeletal muscle from the treated mice revealed a mosaic 
pattern of dystrophin-positive fibers. The percentage of dystrophin-positive fibers 
 35 
 
increased from 7.7% at three weeks to 25.5% of all myofibers at six weeks. 
Similar results were obtained when the mice were injected retro-orbitally. 
Although Long et al. were only able to correct the mutation in a fraction of the 
treated muscle fibers, it was enough to produce significant improvements in 
phenotype and function; Mdx mice exhibited higher grip strength after 
intraperitoneal injection of AAV-CRISPR-Cas9.57 Results from these in vivo gene 
knockdown experiments are promising for CRISPR-Cas9-based treatments that 
can incorporate NHEJ, but are not directly applicable to those that require HDR 
for precise gene insertion. 
 
In Vivo Gene Insertion 
Using hydrodynamic tail vein injection (HTVI) to deliver CRISPR-Cas9 
system components, scientists have been able to gain a better understanding of 
CRISPR-Cas9 systems on the liver in contrast to other organs. HTVI is an 
efficient method of delivery that can be performed on the tails of mice with a 
hepatocyte transfection rate of up to 40%.60 Yin et al. utilized HTVI to treat mice 
with hereditary tyrosinemia type I (HTI) with their CRISPR-Cas9 system.61 HTI is 
caused by mutation of the fumarylacetoacetate hydrolase (FAH) gene locus. 
Without FAH, toxic metabolites will accumulate in the liver and can be fatal.62 
 It was observed that the initial HDR efficiency was just 0.4%, in line with 
previous studies. However, they also discovered through immunohistochemical 
staining that there were large patches of FAH+ hepatocytes after 30 days; these 
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patches expanded up to a third of the liver. Apparently, the edited FAH+ 
hepatocytes were able to outgrow the native FAH- hepatocytes. In their analysis 
of off-target effects, they found that less than 0.3% of the three off-target sites 
sequences contained indels.  
 These results are encouraging for in vivo applications of CRISPR-Cas9 
systems, but should not be generalized with other organs for multiple reasons. 
First, HTVI is not possible for clinical applications. In order to achieve 
comparable transfection rates in human beings, other methods of delivery would 
have to be developed and utilized. Also, the growth advantage displayed by the 
modified hepatocytes is likely an anomaly; more research should be done to 
assess the predictability of this phenomenon. Based on current understanding of 
CRISPR-Cas9, the “true” efficiency of a treatment should be based only on its 
HDR frequency. 
 
Delivery with Nanoparticles   
 The aforementioned NHEJ-inhibiting or HDR-stimulating substances can 
potentially improve the efficiency of CRISPR-Cas9-based treatments, but have 
limited utility in vivo without an efficient method of delivery. Building on their 
previous experiments, Yin et al. attempted to treat HTI mice (FAH-) with 
CRISPR-Cas9 again, but with lipid nanoparticle-mediated delivery of Cas9 
mRNA; sgRNA/HDR template was delivered using AAV2/8 for its liver tropism.64 
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After seven days, up to 6.2% of hepatocytes were FAH+ and 9.5% of FAH 
mRNA expression was restored in treated mice. The mice were also given 2-(2-
nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) water, an inhibitor 
of an enzyme upstream of FAH; this prevents the expansion of FAH-corrected 
cells observed in their previous experiment and allows for accurate measurement 
of the initial HDR efficiency.65 Analysis of off-target effects revealed minimal off-
target mutagenesis. Compared to their previous experiments, Yin et al. were able 
to improve the efficacy of their CRISPR-Cas9 treatment system with the use of 
nanoparticles. 
 Nanoparticles can be designed in various ways for distinct purposes. The 
synthesis and development of zwitterionic amino lipids (ZAL) is significant 
because they are able to simultaneously deliver long RNAs, including Cas9 
mRNA and sgRNAs.65,66 Miller et al. co-delivered Cas9 mRNA and LoxP-sgRNA 
intravenously to genetically engineered mice with homozygous Rosa26 promoter 
Lox-Stop-Lox-tdTomato (tdTO) in all cells.67 If CRISPR-Cas9-induced NHEJ 
occurs, the stop codon will be removed and the cell will gain red fluorescence 
(Figure 8). One week after administration, they were able to detect fluorescent 
tdTO signal in liver, lung, and kidney tissues. Furthermore, tissues harvested two 
months after treatment still exhibited strong fluorescent signals. These results 
indicate that CRISPR-Cas9-based treatments via nanoparticle delivery can be an 
effective and permanent form of therapy. 
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Figure 8. ZNPs enabled non-viral CRISPR-Cas9 editing in vivo. (A) 
Schematic representation of ZNP-delivered Lox-Stop-Lox-tdTO cassette. (B). 
Fluorescent signals were detected in ZNP-CRISPR-Cas9-treated liver, lung, and 
kidney tissues.  
Adapted from Miller et al., 2016. 
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CONCLUSION 
 
 
CRISPR-Cas9 arms scientists with a powerful tool for gene editing and 
has the great potential to be developed for genetic therapy. It has been able to 
modify target sequences in vitro, which makes it applicable for hematological 
diseases. Studies using CRISPR-Cas9-treated HSPCs have been conducted on 
animal models of diseases with promising results. Methods for improving HDR 
efficiency either through inhibition of NHEJ or stimulation of HDR have shown 
success. Also, Cas9 RNA-guided base editors have been shown to be a viable 
alternative gene editing method. For in vivo applications, scientists have been 
able to effectively knockout genes in animal models of diseases as well as insert 
genes under appropriate circumstances. In addition, their efforts have been 
improved by the development of nanoparticles, a significant upgrade for 
delivering CRISPR-Cas9 system components. 
 Ethics have long been a concern surrounding gene editing technology, but 
may be finally beginning give way after a long period of research and data 
collection. Support amongst the scientific community for CRISPR has increased 
for some, but not all applications.68 In particular, support for using CRISPR to edit 
the genomes of germ line cells has been mixed. While the use of CRISPR to 
develop better crops and livestock has gained traction, the manipulation of 
human germ line cells is still a highly controversial subject.68,69 The possibility of 
creating “designer babies” has been a long-standing ethical issue and will likely 
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remain so.69 It is one that is more suited for philosophical debate and transcends 
the scope of this paper.  
Nevertheless, many are enthusiastic about the potential of using CRISPR 
for somatic gene engineering. Researchers and companies have begun to 
request approval from the U.S. Food and Drug Administration to develop 
CRISPR clinical trials for blood diseases such as beta thalassemia and sickle cell 
disease.69 Also, multiple CRISPR trials for cancer are already underway in China. 
The future of CRISPR-Cas9-based medical applications is encouraging and with 
more research, it can provide solutions for patients suffering from hereditary 
diseases and cancers. 
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